fenofibrate All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Merck & Co (September 01, 2015)
Lupin Receives FDA Approval for Fenofibrate Tablets, 54 Mg and 160 Mg
Lupin (August 20, 2015)
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
Merck & Co (August 20, 2015)
First Amendment Decision a Win for Amarin and Physician Plaintiffs
Amarin (August 07, 2015)
Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine
Merck & Co (June 03, 2015)
Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
Tribute Pharmaceuticals Canada (May 21, 2015)
Cipher Reports Financial and Operational Results for Q1 2015
Cipher Pharmaceuticals (May 13, 2015)
Amarin Reports First Quarter 2015 Financial Results and Provides Update on Operations
Amarin (May 08, 2015)
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
Merck & Co (March 16, 2015)
New In Vitro Study Presented at DEUEL Conference on Lipids Suggests Combination Omega-3 Fatty Acid EPA and Atorvastatin May Provide Atheroprotective Benefit
Amarin (March 04, 2015)

Displaying 10 out of a possible 522 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Summary Generic Name Information

Generic Name: fenofibrate
Therapeutic Subcategory:    Anti-hyperlipidaemics

Product Sales Summary

Annual Sales WW - Sales Growth per Year (%)
Rank1 ProductProduct CompanyCompany 2012 2013 2013
Generic Name:2 fenofibrate 1,444 856 -41%
Note: Shaded Cells3

Evaluate - intelligence you can act on

Evaluate delivers market intelligence with standardized, transparent, integrated data that clients rely on.

Choose from a vast array of dynamic reports, customize, edit and download to PDF, Excel or create bespoke reports with expert client support.

Explore Content & Tools


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.  

Register Now